AcuFocus is the manufacturer of IC-8 Apthera, an intraocular lens that received approval from the U.S. Food and Drug Administration in July 2022. The lens was commercially released in January.
“Bausch & Lomb is a legacy name in eyecare with a fully integrated portfolio of offerings in eye health,” Al Waterhouse, president and CEO of AcuFocus, said in a statement obtained by the publication. “We believe Bausch & Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”
AcuFocus has raised over $180 million since it was founded in 2001.
Terms of the sale have not been disclosed.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.